I wasn'the only one moved by the plight of six year old Jasmina Anema, the little girl who died of cancer last week. During her brief life, she inspired thousands of people to get registered as bone marrow donors and she had the opportunity to meet President Obama and pop singer Rihanna.
Rihanna is continuing her support of bone marrow donations in the wake of Jasmina's death, and now she wants Pepsi's help to do it.
This past weekend, the singer announced that she has submitted a request for funding from bosses at beverage giant Pepsi, who have launched the Refresh Project, which hands out $20 million annually to good causes.
Rihanna wants part of the fund to go towards DKMS, which helps to try and find bone marrow donors for the victims of leukemia. After performing at the Refresh Project's launch party, she told reporters how Jasmina had spurred her on to do all she could to battle the condition.
Rihanna says, "She was a very free, fun spirited little girl, full of energy, always happy, always energetic. I always remember she wouldn't sit still. She was always running around, always had a smile on her face. If we win (the funding), this would really help us recruit 4,000 individual donors."
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...